Shockwave Medical, Inc. announced that coronary IVL was included in a treatment guidance document published by the Society of Cardiovascular Angiography and Intervention (SCAI) as a potential therapeutic option in all U.S. catheterization labs - including facilities without on-site surgical backup. The latest guidance SCAI Expert Consensus Statement on PCI Without On-Site Surgical Backup was published online in the Journal of the Society of Cardiovascular Angiography and Intervention (JSCAI). The updated guidelines, which modify the previous 2014 guidelines by no longer restricting recommended treatment to facilities with on-site surgical backup, will now endorse expanded treatment options and access for patients with calcified coronary lesions.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
334.8 USD | -0.01% |
|
+0.01% | +75.69% |
01/07 | Momentum Picks Q3 2024: 5 stocks for the summer | ![]() |
03/06 | Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from S&P 1000 | CI |
1st Jan change | Capi. | |
---|---|---|
+75.69% | 1.26TCr | |
-20.22% | 762.7Cr | |
-3.42% | 584.37Cr | |
+8.16% | 515.91Cr | |
-16.85% | 475.39Cr | |
-12.24% | 416.9Cr | |
+16.22% | 415.9Cr | |
-7.87% | 337.09Cr | |
+25.92% | 207.47Cr | |
-3.47% | 198.85Cr |
- Stock Market
- Equities
- SWAV Stock
- News Shockwave Medical
- ShockWave Medical, Inc. Updates SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status